FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company Profileargenx SE
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ARGX
argenx SE Stock AnalysisComprehensive stock analysis for argenx SE (ARGX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisARGX
ARGX
argenx SE
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ARGX
  1. Home
  2. Stocks
  3. argenx SE

argenx SE

🇺🇸ARGX•NASDAQ

argenx SE

🇺🇸ARGX•NASDAQ
Market cap
$59.19B
P/E ratio
44.34

Your view on ARGX

Mkt Cap
$59.19B
P/E
44.34
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About argenx SE

Industry
Biotechnology
Sector
Healthcare
CEO
Timothy Van Hauwermeiren EMBA,
Headquarters
Laarderhoogtweg 25, Amsterdam, NL
Industry
Biotechnology
Sector
Healthcare
CEO
Timothy Van Hauwermeiren EMBA,
Headquarters
Laarderhoogtweg 25, Amsterdam, NL
Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.

Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB.

The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V.

, VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services.

argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for argenx SE from FRC's valuation model, read against the market price. ARGX last traded at $941.25, 44.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for argenx SE. Starting points for argenx SE: P/E 44.3, EPS $21.16, beta -0.02 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for argenx SE. Trailing twelve-month EPS for argenx SE stands at $21.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$1,143.94

average of 18 firms, last 12 months

 

$1,143.94

Low $861.00

Median $1,135.00

High $1,400.00

 

Analyst Ratings

Buy18 firms, last 12 months
  • Strong Buy0
  • Buy16
  • Hold2
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2018Next QtrJun 2019Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate−$1.49−$0.63$28.35$37.13
Low estimate−$1.78−$0.76$27.15$31.67
High estimate−$1.19−$0.51$32.12$43.77
No. of analysts121199
Year-ago EPS——$19.631—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2018Next QtrJun 2019Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$82.15M$6.98M$6.42B$8.11B
Low estimate$65.72M$5.58M$6.27B$7.60B
High estimate$98.58M$8.37M$6.51B$8.48B
No. of analysts12111412
Year-ago revenue——$4.15B—
Growth——+54.5%—
Recent analyst actions15 rating and price-target changes, latest Oct 27, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for argenx SE. argenx SE has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ARGX15 companies · 8 funds
Compare ARGX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AMGNAmgen Inc.HealthcareDrug Manufacturers - General$240.1B
BIIBBiogen Inc.HealthcareDrug Manufacturers - General$37.2B
INCYIncyte CorporationHealthcareBiotechnology$24.0B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PSYBFPsyBio Therapeutics Corp.HealthcareOTC$1,275
PTCHFPureTech Health plcHealthcareOTC$410.4M
PTCTPTC Therapeutics, Inc.HealthcareNASDAQ$5.0B
PTGXProtagonist Therapeutics, Inc.HealthcareNASDAQ$8.3B
PTHSPelthos Therapeutics Inc.HealthcareAMEX$27.9M
PTIXProtagenic Therapeutics, Inc.HealthcareNASDAQ$470,654
PTNPalatin Technologies, Inc.HealthcareNASDAQ$9.2M
PTX.AXPrescient Therapeutics LimitedHealthcareASX—
PULMPulmatrix, Inc.HealthcareNASDAQ$4.9M
PVCTProvectus Biopharmaceuticals, Inc.HealthcareOTC$18.7M
PVLAPalvella Therapeutics, Inc.HealthcareNASDAQ$2.1B
PXMDPaxMedica, Inc. Common StockHealthcareOTC$37,879
ETFs holding argenx SE
TickerFundFund assets% of the fund
IBBiShares Biotechnology ETF$11.1B in assets3.76%
CGGOCapital Group Global Growth Equity ETF$11.5B in assets1.06%
FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.79%
AVDEAvantis International Equity ETF$19.3B in assets0.16%
FDGAmerican Century Focused Dynamic Growth ETFAmerican Century Focused Dynamic Growth ETFAmerican Century Focused Dynamic Growth ETF$412M in assets1.34%
TGRTT. Rowe Price Growth ETF$1.6B in assets0.57%
FTQIFirst Trust Nasdaq BuyWrite Income ETF$954M in assets0.53%
TOUST. Rowe Price International Equity ETF$1.7B in assets0.45%

Largest holders first, then the funds most concentrated in ARGX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold argenx SE, and how their positions are changing. At a $59.19B market value, institutional positions materially move argenx SE's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming argenx SE. argenx SE is a $59.19B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming argenx SE. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for argenx SE. Coverage tracks argenx SE within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of argenx SE.

ARGX AnalysisGood
Past
2
Growth
5
Health
5
Profit
3
Value
1

News

Latest Market News